Frances Wu

Frances Wu

Auto-generated profile, based on publicly available information

Frances Wu

Department of Ophthalmology, Harvard Medical School, Massachusetts Eye and Ear Infirmary, Boston, United States, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2020 in Ophthalmology Retina
Verified
Journal Article
Closed access
JSJay Stewart
Jay Stewart
RLRicardo Lamy
Ricardo Lamy
FWFrances Wu
Frances Wu
JKJeremy D. Keenan
Jeremy D. Keenan

22 February 2021 in Seminars in Ophthalmology
Verified
Journal Article
Closed access
FWFrances Wu
Frances Wu
DEDean Eliott
Dean Eliott
While innovations in the surgical management of retinal detachment (RD) with proliferative vitreoretinopathy (PVR) have significantly improved anatomic and visual outcomes over the years, recurrent RD due to PVR remains the major limitation to success. There are currently no medical therapies proven to be effective against PVR in humans. Increased understanding of the pathophysiology and risk factors for PVR have helped guide investigations for molecular targets. Drugs that counteract inflammation, proliferation, and growth factors are the leading candidates for treatment of PVR. This review discusses the ongoing search for pharmacologic therapies, with an emphasis on the results of recent clinical investigations.

8 January 2022 in Ophthalmology Retina
Verified
Journal Article
Closed access
FWFrances Wu
Frances Wu
MMMark P. McGarrey
Mark P. McGarrey
KGKennedy R. Geenen
Kennedy R. Geenen
ASAlison H. Skalet
Alison H. Skalet
FGFlorian H. Guillot
Florian H. Guillot
MAMary E. Aronow
Mary E. Aronow

2 September 2022 in Ocular Immunology and Inflammation
Verified
Journal Article
Closed access
IBIsaac D. Bleicher
Isaac D. Bleicher
DBDaniel Brill
Daniel Brill
FWFrances Wu
Frances Wu
LSLucia Sobrin
Lucia Sobrin
NPNimesh Patel
Nimesh Patel
A 49-year-old man presented with acute unilateral blurred vision one week after SARS-CoV-2 vaccination. A unilateral serous detachment of the macula, intraretinal hemorrhages, vitritis, and anterior chamber cell was found. Diagnostic testing was negative for infectious and inflammatory causes, and a diagnosis of acute idiopathic maculopathy (AIM) was made. Symptoms and serous detachment resolved over 12 weeks, with residual retinal pigment epithelial changes consistent with the disease course. AIM is a rare diagnosis that presented in close proximity to SARS-CoV-2 vaccination without evidence of coxsackievirus infection. Further research is necessary to clarify an association between this vaccine and uveitis.

19 September 2023 in Ocular Oncology and Pathology
Verified
Journal Article
Closed access
PDF file
FWFrances Wu
Frances Wu
ALAnne Marie Lane
Anne Marie Lane
ATAlexei Trofimov
Alexei Trofimov
HSHelen A. Shih
Helen A. Shih
EGEvangelos S. Gragoudas
Evangelos S. Gragoudas
IKIvana K. Kim
Ivana K. Kim
Introduction: Vision loss is common in patients treated with radiotherapy for uveal melanoma. With proton beam irradiation (PBI), the prescribed dose is delivered to the tumor with a sharp dose reduction outside the target volume. However, radiation complications are likely to develop when tumors are located near the optic nerve or fovea. Treatment with light-activated AU-011 (belzupacap sarotalocan), an investigational drug which specifically targets tumor cells, may avoid these complications. We evaluated outcomes in a historical group of patients who fit eligibility criteria for AU-011 therapy and were treated with PBI. Methods: A consecutive series of patients who received PBI for small choroidal melanoma at a single center between 1986 and 2016 were identified. Consistent with eligibility criteria in clinical trials of AU-011, patients were included when tumor dimensions did not exceed 2.5 mm in maximum thickness and 10.0 mm in largest basal diameter (LBD). Snellen visual acuities were converted to logMAR for analysis. Visual acuity outcomes were analyzed in patients with an initial acuity of logMAR 0.7 or better (equivalent to Snellen 20/100). Rates of visual acuity loss and mortality were calculated using the Kaplan-Meier method. Acuity loss by tumor location was compared using log-rank testing. Rates of tumor recurrence, neovascular glaucoma (NVG), and eye loss were also described. Results: Two hundred and 22 patients were included in the study. The median age was 60.7 years (range 21.3–94.8 years). Median tumor thickness was 2.0 mm (range 1.2–2.5 mm), and median LBD was 8.0 mm (range 4.0–10.0 mm). Median follow-up was 6.9 years (range 1.0–30.2 years). In 204 patients with a baseline logMAR visual acuity of 0.7 or better, the mean baseline acuity was 0.15 (equivalent to Snellen 20/25), which decreased to 0.52 (approximately Snellen 20/70) by 5 years after PBI. Visual outcomes were significantly worse for patients with tumors located within 3 mm of the optic disc and/or fovea. Tumor recurrence (1.4%), NVG (4.5%), and eye loss (2.7%) were uncommon. Discussion: Despite the advantageous dose distribution of protons, over half of patients with small choroidal melanomas located near the optic disc or fovea had a visual acuity equivalent to 20/80 or worse at 5 years after PBI. Treatment with AU-011 may allow better vision preservation in small tumors that carry a high risk of vision loss with radiotherapy.

2 June 2023 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
FWFrances Wu
Frances Wu
ALAnne Marie Lane
Anne Marie Lane
MOMonica M. Oxenreiter
Monica M. Oxenreiter
EGEvangelos S. Gragoudas
Evangelos S. Gragoudas
IKIvana K. Kim
Ivana K. Kim